InflaRx N.V.
NASDAQ:IFRX
1.56 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | InflaRx N.V. |
Symbool | IFRX |
Munteenheid | USD |
Prijs | 1.565 |
Beurswaarde | 92,152,365 |
Dividendpercentage | 0% |
52-weken bereik | 1.14 - 2.1 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Niels C. Riedemann M.D., Ph.D. |
Website | https://www.inflarx.de |
An error occurred while fetching data.
Over InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)